New Launch21 Mar 2026, 12:31 pm
Alkem Laboratories launches semaglutide injection in India at weekly therapy cost starting INR 450
AI Summary
Alkem Laboratories Ltd. has announced the launch of semaglutide injection in India under the brand names ‘Semasize’, ‘Obesema’ and ‘Hepaglide’. The company has priced its semaglutide pre-filled disposable injection pen at INR 1,800 for a month’s dosage, which translates into a weekly cost of INR 450. Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management. The reusable pen offered by Alkem enables patients to replace only the medication cartridge, reducing cost and helping better patient adherence to treatment.
Key Highlights
- Alkem Laboratories launches semaglutide injection in India under the brand names ‘Semasize’, ‘Obesema’ and ‘Hepaglide’
- Semaglutide is priced at INR 1,800 for a month’s dosage, translating into a weekly cost of INR 450
- Alkem received approval from DCGI for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management
- Alkem offers a reusable injection pen for semaglutide administration, reducing cost and helping better patient adherence to treatment
- Semaglutide is administered as a subcutaneous injection, once weekly